These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10397617)

  • 1. Evaluation of truncated areas in the assessment of bioequivalence of immediate release formulations of drugs with long half-lives and of Cmax with different dissolution rates.
    Sathe P; Venitz J; Lesko L
    Pharm Res; 1999 Jun; 16(6):939-43. PubMed ID: 10397617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of bioequivalence of highly variable drugs using clinical trial simulations. II: Comparison of single and multiple-dose trials using AUC and Cmax.
    el-Tahtawy AA; Tozer TN; Harrison F; Lesko L; Williams R
    Pharm Res; 1998 Jan; 15(1):98-104. PubMed ID: 9487554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of characteristics and their bioequivalence ranges for the comparison of absorption rates of immediate-release drug formulations.
    Schall R; Luus HG; Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):323-8. PubMed ID: 7952792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption rate vs. exposure: which is more useful for bioequivalence testing?
    Tozer TN; Bois FY; Hauck WW; Chen ML; Williams RL
    Pharm Res; 1996 Mar; 13(3):453-6. PubMed ID: 8692741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs.
    Hammami MM; De Padua SJS; Hussein R; Al Gaai E; Khodr NA; Al-Swayeh R; Alvi SN; Binhashim N
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):78. PubMed ID: 29216899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence: performance of several measures of extent of absorption.
    Bois FY; Tozer TN; Hauck WW; Chen ML; Patnaik R; Williams RL
    Pharm Res; 1994 May; 11(5):715-22. PubMed ID: 8058642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of absorption rates in bioequivalence studies of immediate release drug formulations.
    Schall R; Luus HG
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):153-9. PubMed ID: 1592542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies.
    Lacey LF; Keene ON; Duquesnoy C; Bye A
    J Pharm Sci; 1994 Feb; 83(2):212-5. PubMed ID: 8169791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of truncated areas to measure extent of drug absorption in bioequivalence studies: effects of drug absorption rate and elimination rate variability on this metric.
    Kharidia J; Jackson AJ; Ouderkirk LA
    Pharm Res; 1999 Jan; 16(1):130-4. PubMed ID: 9950291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence study of two azithromycin formulations in healthy subjects.
    Setiawati E; Deniati SH; Yunaidi DA; Handayani LR; Harinanto G; Santoso ID; Sari AP; Rimainar A
    Arzneimittelforschung; 2009; 59(9):471-5. PubMed ID: 19856795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Truncated area under the curve as a measure of relative extent of bioavailability: evaluation using experimental data and Monte Carlo simulations.
    Gaudreault J; Potvin D; Lavigne J; Lalonde RL
    Pharm Res; 1998 Oct; 15(10):1621-9. PubMed ID: 9794507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioequivalence evaluation of two brands of lisinopril tablets by in vitro comparative dissolution test and in vivo bioequivalence test.
    Shin MC; Kim JK; Kim CK
    Arzneimittelforschung; 2008; 58(1):11-7. PubMed ID: 18368945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence study of two perindopril erbumine tablet formulations in healthy volunteers.
    Setiawati E; Deniati SH; Yunaidi DA; Handayani LR; Santoso ID; Arland JA; Setiawati A; Lian LY
    Arzneimittelforschung; 2011; 61(4):234-8. PubMed ID: 21650082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence study of two clopidogrel film-coated tablet formulations in healthy volunteers.
    Setiawati E; Yunaidi DA; Handayani LR; Santoso ID; Setiawati A; Tjandrawinata RR
    Arzneimittelforschung; 2011; 61(12):681-4. PubMed ID: 22282954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of bioequivalence of highly variable drugs using Monte Carlo simulations. I. Estimation of rate of absorption for single and multiple dose trials using Cmax.
    el-Tahtawy AA; Jackson AJ; Ludden TM
    Pharm Res; 1995 Nov; 12(11):1634-41. PubMed ID: 8592662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissolution modeling of bead formulations and predictions of bioequivalence for a highly soluble, highly permeable drug.
    Sperry DC; Thomas SJ; Lobo E
    Mol Pharm; 2010 Oct; 7(5):1450-7. PubMed ID: 20704266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles.
    Kwon M; Yeom D; Kim NA; Choi du H; Park J; Wang H; Yoo SD; Jeong SH
    Arch Pharm Res; 2015 Jan; 38(1):73-80. PubMed ID: 24627339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How critical is the duration of the sampling scheme for the determination of half-life, characterization of exposure and assessment of bioequivalence?
    Colucci P; Turgeon J; Ducharme MP
    J Pharm Pharm Sci; 2011; 14(2):217-26. PubMed ID: 21733410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.